Loading…
Low rate of COVID‐19 pneumonia in kidney transplant recipients—A battle between infection and immune response?
Background With COVID‐19 pandemic, concerns about kidney transplant recipients are rising. However, the incidence, clinical course, outcome, and predictive factors of disease severity are obscured. Methods We describe clinical and laboratory manifestations, radiologic findings, clinical course, and...
Saved in:
Published in: | Transplant infectious disease 2020-10, Vol.22 (5), p.e13406-n/a |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4436-29dd7c5037ad55ddce55ec116e9c5dbf0f17825dda2bb51046f4c834541618f43 |
---|---|
cites | cdi_FETCH-LOGICAL-c4436-29dd7c5037ad55ddce55ec116e9c5dbf0f17825dda2bb51046f4c834541618f43 |
container_end_page | n/a |
container_issue | 5 |
container_start_page | e13406 |
container_title | Transplant infectious disease |
container_volume | 22 |
creator | Ghaffari Rahbar, Maryam Nafar, Mohsen Khoshdel, Alireza Dalili, Nooshin Abrishami, Alireza Firouzan, Ahmad Poorrezagholi, Fatemeh Samadian, Fariba Ziaie, Shadi Fatemizadeh, Somayeh Samavat, Shiva |
description | Background
With COVID‐19 pandemic, concerns about kidney transplant recipients are rising. However, the incidence, clinical course, outcome, and predictive factors of disease severity are obscured.
Methods
We describe clinical and laboratory manifestations, radiologic findings, clinical course, and finally outcome of kidney transplant recipients with COVID‐19 pneumonia.
Results
Of 2493 kidney transplant recipients under follow‐up in our clinic, 19 cases (4 cases diagnosed based on radiologic findings) were admitted. The mean age of patients was 47.6 ± 12.4 years, and the mean time from transplantation was 115.6 ± 70.3 months. Lymphopenia and eosinopenia were 84.2% and 78.9%, respectively. Nine patients did not survive the hospital course. History of acute rejection during the past 12 months, diabetes, higher N/L ratio, lower platelet count, elevated N/L x CRP, higher levels of LDH, positive D‐dimer, higher troponin, and prolonged PT were associated with mortality. Among patients with positive COVID‐19 test, history of acute rejection, low platelet count, and positive D‐dimer were associated with poor outcome. Treatment with cyclosporine was associated with better clinical outcome.
Conclusions
Low rate of admission in transplant recipients specially in the very first years of transplantation might be due to protective effects of immunosuppressive agents against cytokine storm or modification of immunity function. We suggest evaluation of T‐cell number, function, and cytokine profile as a guide to manage COVID‐19 mainly in patients with higher risk of mortality. |
doi_str_mv | 10.1111/tid.13406 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7404525</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2423520227</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4436-29dd7c5037ad55ddce55ec116e9c5dbf0f17825dda2bb51046f4c834541618f43</originalsourceid><addsrcrecordid>eNp1kU1uFDEQhS0EImFgwQWQJTaw6MS__bMhiiYkjDRSNoGt5XZXg0O33dhuRrPLEVhwwpwEJ5NEAQlvylJ976mqHkKvKTmg-R0m2x1QLkj5BO1T3jQFJyV7evuvC8YqvodexHhJCK0a0TxHe5yVUnBZ7aOw9hscdALse7w8_7I6ub76RRs8OZhH76zG1uHvtnOwxSloF6dBu4QDGDtZcCleX_0-xq1OaQDcQtoAuCzpwSTrHdauw3YcZwdZEifvIhy9RM96PUR4dVcX6PPpx4vlp2J9frZaHq8LIwQvC9Z0XWUk4ZXupOw6A1KCobSExsiu7UlPq5rlhmZtKykRZS9MzYUUtKR1L_gCfdj5TnM7Qta7vMCgpmBHHbbKa6v-7jj7TX31P1UliJBMZoN3dwbB_5ghJjXaaGDIFwA_R8UE45KRmwMv0Nt_0Es_B5fXy5QUJZOkqTP1fkeZ4GMM0D8MQ4m6SVLlJNVtkpl983j6B_I-ugwc7oCNHWD7fyd1sTrZWf4BmoGq3Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2454625098</pqid></control><display><type>article</type><title>Low rate of COVID‐19 pneumonia in kidney transplant recipients—A battle between infection and immune response?</title><source>Wiley</source><creator>Ghaffari Rahbar, Maryam ; Nafar, Mohsen ; Khoshdel, Alireza ; Dalili, Nooshin ; Abrishami, Alireza ; Firouzan, Ahmad ; Poorrezagholi, Fatemeh ; Samadian, Fariba ; Ziaie, Shadi ; Fatemizadeh, Somayeh ; Samavat, Shiva</creator><creatorcontrib>Ghaffari Rahbar, Maryam ; Nafar, Mohsen ; Khoshdel, Alireza ; Dalili, Nooshin ; Abrishami, Alireza ; Firouzan, Ahmad ; Poorrezagholi, Fatemeh ; Samadian, Fariba ; Ziaie, Shadi ; Fatemizadeh, Somayeh ; Samavat, Shiva</creatorcontrib><description>Background
With COVID‐19 pandemic, concerns about kidney transplant recipients are rising. However, the incidence, clinical course, outcome, and predictive factors of disease severity are obscured.
Methods
We describe clinical and laboratory manifestations, radiologic findings, clinical course, and finally outcome of kidney transplant recipients with COVID‐19 pneumonia.
Results
Of 2493 kidney transplant recipients under follow‐up in our clinic, 19 cases (4 cases diagnosed based on radiologic findings) were admitted. The mean age of patients was 47.6 ± 12.4 years, and the mean time from transplantation was 115.6 ± 70.3 months. Lymphopenia and eosinopenia were 84.2% and 78.9%, respectively. Nine patients did not survive the hospital course. History of acute rejection during the past 12 months, diabetes, higher N/L ratio, lower platelet count, elevated N/L x CRP, higher levels of LDH, positive D‐dimer, higher troponin, and prolonged PT were associated with mortality. Among patients with positive COVID‐19 test, history of acute rejection, low platelet count, and positive D‐dimer were associated with poor outcome. Treatment with cyclosporine was associated with better clinical outcome.
Conclusions
Low rate of admission in transplant recipients specially in the very first years of transplantation might be due to protective effects of immunosuppressive agents against cytokine storm or modification of immunity function. We suggest evaluation of T‐cell number, function, and cytokine profile as a guide to manage COVID‐19 mainly in patients with higher risk of mortality.</description><identifier>ISSN: 1398-2273</identifier><identifier>EISSN: 1399-3062</identifier><identifier>DOI: 10.1111/tid.13406</identifier><identifier>PMID: 32654357</identifier><language>eng</language><publisher>Denmark: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Antiviral Agents - therapeutic use ; Calcium-binding protein ; Cell number ; COVID-19 ; COVID-19 - complications ; COVID-19 - diagnosis ; COVID-19 - drug therapy ; COVID-19 - epidemiology ; COVID-19 - immunology ; Cyclosporins ; Cytokine Release Syndrome - diagnosis ; Cytokine Release Syndrome - epidemiology ; Cytokine Release Syndrome - immunology ; Cytokine Release Syndrome - virology ; Cytokine storm ; Cytokines ; Cytokines - blood ; Cytokines - immunology ; Diabetes mellitus ; Dimers ; Eosinopenia ; Female ; Follow-Up Studies ; Graft rejection ; Graft Rejection - epidemiology ; Graft Rejection - immunology ; Graft Rejection - prevention & control ; Humans ; Immune response ; Immune system ; Immunity - drug effects ; Immunocompromised Host ; immunosuppressive ; Immunosuppressive agents ; Immunosuppressive Agents - therapeutic use ; Iran - epidemiology ; Kidney transplantation ; Kidney Transplantation - adverse effects ; Kidney transplants ; Kidneys ; Lung - diagnostic imaging ; Lymphocyte Count ; Lymphopenia ; Male ; Middle Aged ; Mortality ; N/L ratio ; Original Report ; Original Reports ; Pandemics ; Patients ; Platelets ; Pneumonia ; Rejection ; SARS-CoV-2 - immunology ; SARS-CoV-2 - isolation & purification ; T-Lymphocytes - immunology ; Tomography, X-Ray Computed ; Transplant Recipients - statistics & numerical data ; Transplantation ; Troponin ; Viral diseases</subject><ispartof>Transplant infectious disease, 2020-10, Vol.22 (5), p.e13406-n/a</ispartof><rights>2020 Wiley Periodicals LLC</rights><rights>2020 Wiley Periodicals LLC.</rights><rights>2020 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4436-29dd7c5037ad55ddce55ec116e9c5dbf0f17825dda2bb51046f4c834541618f43</citedby><cites>FETCH-LOGICAL-c4436-29dd7c5037ad55ddce55ec116e9c5dbf0f17825dda2bb51046f4c834541618f43</cites><orcidid>0000-0002-4358-470X ; 0000-0001-7534-8309 ; 0000-0001-5636-2666 ; 0000-0002-1618-0937 ; 0000-0002-5280-0603 ; 0000-0002-1781-1091 ; 0000-0001-6707-7844 ; 0000-0002-8274-397X ; 0000-0001-9311-5429 ; 0000-0003-4004-3198 ; 0000-0002-1330-6207</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32654357$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghaffari Rahbar, Maryam</creatorcontrib><creatorcontrib>Nafar, Mohsen</creatorcontrib><creatorcontrib>Khoshdel, Alireza</creatorcontrib><creatorcontrib>Dalili, Nooshin</creatorcontrib><creatorcontrib>Abrishami, Alireza</creatorcontrib><creatorcontrib>Firouzan, Ahmad</creatorcontrib><creatorcontrib>Poorrezagholi, Fatemeh</creatorcontrib><creatorcontrib>Samadian, Fariba</creatorcontrib><creatorcontrib>Ziaie, Shadi</creatorcontrib><creatorcontrib>Fatemizadeh, Somayeh</creatorcontrib><creatorcontrib>Samavat, Shiva</creatorcontrib><title>Low rate of COVID‐19 pneumonia in kidney transplant recipients—A battle between infection and immune response?</title><title>Transplant infectious disease</title><addtitle>Transpl Infect Dis</addtitle><description>Background
With COVID‐19 pandemic, concerns about kidney transplant recipients are rising. However, the incidence, clinical course, outcome, and predictive factors of disease severity are obscured.
Methods
We describe clinical and laboratory manifestations, radiologic findings, clinical course, and finally outcome of kidney transplant recipients with COVID‐19 pneumonia.
Results
Of 2493 kidney transplant recipients under follow‐up in our clinic, 19 cases (4 cases diagnosed based on radiologic findings) were admitted. The mean age of patients was 47.6 ± 12.4 years, and the mean time from transplantation was 115.6 ± 70.3 months. Lymphopenia and eosinopenia were 84.2% and 78.9%, respectively. Nine patients did not survive the hospital course. History of acute rejection during the past 12 months, diabetes, higher N/L ratio, lower platelet count, elevated N/L x CRP, higher levels of LDH, positive D‐dimer, higher troponin, and prolonged PT were associated with mortality. Among patients with positive COVID‐19 test, history of acute rejection, low platelet count, and positive D‐dimer were associated with poor outcome. Treatment with cyclosporine was associated with better clinical outcome.
Conclusions
Low rate of admission in transplant recipients specially in the very first years of transplantation might be due to protective effects of immunosuppressive agents against cytokine storm or modification of immunity function. We suggest evaluation of T‐cell number, function, and cytokine profile as a guide to manage COVID‐19 mainly in patients with higher risk of mortality.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Calcium-binding protein</subject><subject>Cell number</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - drug therapy</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - immunology</subject><subject>Cyclosporins</subject><subject>Cytokine Release Syndrome - diagnosis</subject><subject>Cytokine Release Syndrome - epidemiology</subject><subject>Cytokine Release Syndrome - immunology</subject><subject>Cytokine Release Syndrome - virology</subject><subject>Cytokine storm</subject><subject>Cytokines</subject><subject>Cytokines - blood</subject><subject>Cytokines - immunology</subject><subject>Diabetes mellitus</subject><subject>Dimers</subject><subject>Eosinopenia</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Graft rejection</subject><subject>Graft Rejection - epidemiology</subject><subject>Graft Rejection - immunology</subject><subject>Graft Rejection - prevention & control</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunity - drug effects</subject><subject>Immunocompromised Host</subject><subject>immunosuppressive</subject><subject>Immunosuppressive agents</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Iran - epidemiology</subject><subject>Kidney transplantation</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Kidney transplants</subject><subject>Kidneys</subject><subject>Lung - diagnostic imaging</subject><subject>Lymphocyte Count</subject><subject>Lymphopenia</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>N/L ratio</subject><subject>Original Report</subject><subject>Original Reports</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Platelets</subject><subject>Pneumonia</subject><subject>Rejection</subject><subject>SARS-CoV-2 - immunology</subject><subject>SARS-CoV-2 - isolation & purification</subject><subject>T-Lymphocytes - immunology</subject><subject>Tomography, X-Ray Computed</subject><subject>Transplant Recipients - statistics & numerical data</subject><subject>Transplantation</subject><subject>Troponin</subject><subject>Viral diseases</subject><issn>1398-2273</issn><issn>1399-3062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kU1uFDEQhS0EImFgwQWQJTaw6MS__bMhiiYkjDRSNoGt5XZXg0O33dhuRrPLEVhwwpwEJ5NEAQlvylJ976mqHkKvKTmg-R0m2x1QLkj5BO1T3jQFJyV7evuvC8YqvodexHhJCK0a0TxHe5yVUnBZ7aOw9hscdALse7w8_7I6ub76RRs8OZhH76zG1uHvtnOwxSloF6dBu4QDGDtZcCleX_0-xq1OaQDcQtoAuCzpwSTrHdauw3YcZwdZEifvIhy9RM96PUR4dVcX6PPpx4vlp2J9frZaHq8LIwQvC9Z0XWUk4ZXupOw6A1KCobSExsiu7UlPq5rlhmZtKykRZS9MzYUUtKR1L_gCfdj5TnM7Qta7vMCgpmBHHbbKa6v-7jj7TX31P1UliJBMZoN3dwbB_5ghJjXaaGDIFwA_R8UE45KRmwMv0Nt_0Es_B5fXy5QUJZOkqTP1fkeZ4GMM0D8MQ4m6SVLlJNVtkpl983j6B_I-ugwc7oCNHWD7fyd1sTrZWf4BmoGq3Q</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Ghaffari Rahbar, Maryam</creator><creator>Nafar, Mohsen</creator><creator>Khoshdel, Alireza</creator><creator>Dalili, Nooshin</creator><creator>Abrishami, Alireza</creator><creator>Firouzan, Ahmad</creator><creator>Poorrezagholi, Fatemeh</creator><creator>Samadian, Fariba</creator><creator>Ziaie, Shadi</creator><creator>Fatemizadeh, Somayeh</creator><creator>Samavat, Shiva</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4358-470X</orcidid><orcidid>https://orcid.org/0000-0001-7534-8309</orcidid><orcidid>https://orcid.org/0000-0001-5636-2666</orcidid><orcidid>https://orcid.org/0000-0002-1618-0937</orcidid><orcidid>https://orcid.org/0000-0002-5280-0603</orcidid><orcidid>https://orcid.org/0000-0002-1781-1091</orcidid><orcidid>https://orcid.org/0000-0001-6707-7844</orcidid><orcidid>https://orcid.org/0000-0002-8274-397X</orcidid><orcidid>https://orcid.org/0000-0001-9311-5429</orcidid><orcidid>https://orcid.org/0000-0003-4004-3198</orcidid><orcidid>https://orcid.org/0000-0002-1330-6207</orcidid></search><sort><creationdate>202010</creationdate><title>Low rate of COVID‐19 pneumonia in kidney transplant recipients—A battle between infection and immune response?</title><author>Ghaffari Rahbar, Maryam ; Nafar, Mohsen ; Khoshdel, Alireza ; Dalili, Nooshin ; Abrishami, Alireza ; Firouzan, Ahmad ; Poorrezagholi, Fatemeh ; Samadian, Fariba ; Ziaie, Shadi ; Fatemizadeh, Somayeh ; Samavat, Shiva</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4436-29dd7c5037ad55ddce55ec116e9c5dbf0f17825dda2bb51046f4c834541618f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Calcium-binding protein</topic><topic>Cell number</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - drug therapy</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - immunology</topic><topic>Cyclosporins</topic><topic>Cytokine Release Syndrome - diagnosis</topic><topic>Cytokine Release Syndrome - epidemiology</topic><topic>Cytokine Release Syndrome - immunology</topic><topic>Cytokine Release Syndrome - virology</topic><topic>Cytokine storm</topic><topic>Cytokines</topic><topic>Cytokines - blood</topic><topic>Cytokines - immunology</topic><topic>Diabetes mellitus</topic><topic>Dimers</topic><topic>Eosinopenia</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Graft rejection</topic><topic>Graft Rejection - epidemiology</topic><topic>Graft Rejection - immunology</topic><topic>Graft Rejection - prevention & control</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunity - drug effects</topic><topic>Immunocompromised Host</topic><topic>immunosuppressive</topic><topic>Immunosuppressive agents</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Iran - epidemiology</topic><topic>Kidney transplantation</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Kidney transplants</topic><topic>Kidneys</topic><topic>Lung - diagnostic imaging</topic><topic>Lymphocyte Count</topic><topic>Lymphopenia</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>N/L ratio</topic><topic>Original Report</topic><topic>Original Reports</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Platelets</topic><topic>Pneumonia</topic><topic>Rejection</topic><topic>SARS-CoV-2 - immunology</topic><topic>SARS-CoV-2 - isolation & purification</topic><topic>T-Lymphocytes - immunology</topic><topic>Tomography, X-Ray Computed</topic><topic>Transplant Recipients - statistics & numerical data</topic><topic>Transplantation</topic><topic>Troponin</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghaffari Rahbar, Maryam</creatorcontrib><creatorcontrib>Nafar, Mohsen</creatorcontrib><creatorcontrib>Khoshdel, Alireza</creatorcontrib><creatorcontrib>Dalili, Nooshin</creatorcontrib><creatorcontrib>Abrishami, Alireza</creatorcontrib><creatorcontrib>Firouzan, Ahmad</creatorcontrib><creatorcontrib>Poorrezagholi, Fatemeh</creatorcontrib><creatorcontrib>Samadian, Fariba</creatorcontrib><creatorcontrib>Ziaie, Shadi</creatorcontrib><creatorcontrib>Fatemizadeh, Somayeh</creatorcontrib><creatorcontrib>Samavat, Shiva</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Transplant infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghaffari Rahbar, Maryam</au><au>Nafar, Mohsen</au><au>Khoshdel, Alireza</au><au>Dalili, Nooshin</au><au>Abrishami, Alireza</au><au>Firouzan, Ahmad</au><au>Poorrezagholi, Fatemeh</au><au>Samadian, Fariba</au><au>Ziaie, Shadi</au><au>Fatemizadeh, Somayeh</au><au>Samavat, Shiva</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low rate of COVID‐19 pneumonia in kidney transplant recipients—A battle between infection and immune response?</atitle><jtitle>Transplant infectious disease</jtitle><addtitle>Transpl Infect Dis</addtitle><date>2020-10</date><risdate>2020</risdate><volume>22</volume><issue>5</issue><spage>e13406</spage><epage>n/a</epage><pages>e13406-n/a</pages><issn>1398-2273</issn><eissn>1399-3062</eissn><abstract>Background
With COVID‐19 pandemic, concerns about kidney transplant recipients are rising. However, the incidence, clinical course, outcome, and predictive factors of disease severity are obscured.
Methods
We describe clinical and laboratory manifestations, radiologic findings, clinical course, and finally outcome of kidney transplant recipients with COVID‐19 pneumonia.
Results
Of 2493 kidney transplant recipients under follow‐up in our clinic, 19 cases (4 cases diagnosed based on radiologic findings) were admitted. The mean age of patients was 47.6 ± 12.4 years, and the mean time from transplantation was 115.6 ± 70.3 months. Lymphopenia and eosinopenia were 84.2% and 78.9%, respectively. Nine patients did not survive the hospital course. History of acute rejection during the past 12 months, diabetes, higher N/L ratio, lower platelet count, elevated N/L x CRP, higher levels of LDH, positive D‐dimer, higher troponin, and prolonged PT were associated with mortality. Among patients with positive COVID‐19 test, history of acute rejection, low platelet count, and positive D‐dimer were associated with poor outcome. Treatment with cyclosporine was associated with better clinical outcome.
Conclusions
Low rate of admission in transplant recipients specially in the very first years of transplantation might be due to protective effects of immunosuppressive agents against cytokine storm or modification of immunity function. We suggest evaluation of T‐cell number, function, and cytokine profile as a guide to manage COVID‐19 mainly in patients with higher risk of mortality.</abstract><cop>Denmark</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32654357</pmid><doi>10.1111/tid.13406</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-4358-470X</orcidid><orcidid>https://orcid.org/0000-0001-7534-8309</orcidid><orcidid>https://orcid.org/0000-0001-5636-2666</orcidid><orcidid>https://orcid.org/0000-0002-1618-0937</orcidid><orcidid>https://orcid.org/0000-0002-5280-0603</orcidid><orcidid>https://orcid.org/0000-0002-1781-1091</orcidid><orcidid>https://orcid.org/0000-0001-6707-7844</orcidid><orcidid>https://orcid.org/0000-0002-8274-397X</orcidid><orcidid>https://orcid.org/0000-0001-9311-5429</orcidid><orcidid>https://orcid.org/0000-0003-4004-3198</orcidid><orcidid>https://orcid.org/0000-0002-1330-6207</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1398-2273 |
ispartof | Transplant infectious disease, 2020-10, Vol.22 (5), p.e13406-n/a |
issn | 1398-2273 1399-3062 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7404525 |
source | Wiley |
subjects | Adult Aged Antiviral Agents - therapeutic use Calcium-binding protein Cell number COVID-19 COVID-19 - complications COVID-19 - diagnosis COVID-19 - drug therapy COVID-19 - epidemiology COVID-19 - immunology Cyclosporins Cytokine Release Syndrome - diagnosis Cytokine Release Syndrome - epidemiology Cytokine Release Syndrome - immunology Cytokine Release Syndrome - virology Cytokine storm Cytokines Cytokines - blood Cytokines - immunology Diabetes mellitus Dimers Eosinopenia Female Follow-Up Studies Graft rejection Graft Rejection - epidemiology Graft Rejection - immunology Graft Rejection - prevention & control Humans Immune response Immune system Immunity - drug effects Immunocompromised Host immunosuppressive Immunosuppressive agents Immunosuppressive Agents - therapeutic use Iran - epidemiology Kidney transplantation Kidney Transplantation - adverse effects Kidney transplants Kidneys Lung - diagnostic imaging Lymphocyte Count Lymphopenia Male Middle Aged Mortality N/L ratio Original Report Original Reports Pandemics Patients Platelets Pneumonia Rejection SARS-CoV-2 - immunology SARS-CoV-2 - isolation & purification T-Lymphocytes - immunology Tomography, X-Ray Computed Transplant Recipients - statistics & numerical data Transplantation Troponin Viral diseases |
title | Low rate of COVID‐19 pneumonia in kidney transplant recipients—A battle between infection and immune response? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A50%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20rate%20of%20COVID%E2%80%9019%20pneumonia%20in%20kidney%20transplant%20recipients%E2%80%94A%20battle%20between%20infection%20and%20immune%20response?&rft.jtitle=Transplant%20infectious%20disease&rft.au=Ghaffari%20Rahbar,%20Maryam&rft.date=2020-10&rft.volume=22&rft.issue=5&rft.spage=e13406&rft.epage=n/a&rft.pages=e13406-n/a&rft.issn=1398-2273&rft.eissn=1399-3062&rft_id=info:doi/10.1111/tid.13406&rft_dat=%3Cproquest_pubme%3E2423520227%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4436-29dd7c5037ad55ddce55ec116e9c5dbf0f17825dda2bb51046f4c834541618f43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2454625098&rft_id=info:pmid/32654357&rfr_iscdi=true |